AstraZeneca
AstraZeneca

Financials • AstraZeneca

AZN

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2022
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2022
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2023
45,811
13,580
0,234
13%
1.9
39,143
15%
21,532
1.6
10,345
-3,778
-6,567
6,567
0
-4,500
76%
2.2%
12/2023
45,811
13,580
0,234
13%
1.9
39,143
15%
21,532
1.6
10,345
-3,778
-6,567
6,567
0
-4,500
76%
2.2%
12/2024
54,073
16,691
0,234
13%
2.3
40,786
17%
23,189
1.4
11,861
-4,586
-3,996
7,275
-81
-4,629
66%
1.1%
12/2024
54,073
16,691
0,234
13%
2.3
40,786
17%
23,189
1.4
11,861
-4,586
-3,996
7,275
-81
-4,629
66%
1.1%
12/2025
58,739
19,476
01,345
17%
3.3
48,667
21%
22,078
1.1
14,575
-5,905
-7,544
8,670
-521
-4,971
49%
0.91%

To see all financials—including updated, you must be Premium.